CX717

From Wikipedia, the free encyclopedia.

CX717 was created by Dr Gary Lynch from the University of California. CX717 is part of a family of compounds called ampakines which work by boosting the brain chemical glutamate responsible for learning and recall.

In 2005 The U.S. Food and Drug Administration (FDA) accepted Cortex Pharmaceuticals' IND (Investigational New Drug) application to initiate pilot Phase II clinical trials in the United States.

Facilitation of Task Performance and Removal of the Effects of Sleep Deprivation by an Ampakine (CX717) in Nonhuman Primates

Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466

Dr. Gary Lynch